Endotoxins and inflammation in hemodialysis patients

Hemodialysis International

Volumn 17, Issue 3, 2013, Pages 359-365

  El Koraie, Ahmed F ^a   Naga, Yasmine S ^a   Saaran, Amina M ^a   Farahat, Nahla G ^a   Hazzah, Walaa A ^b  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b High Institute of Public Health Egypt   (Egypt)

Author keywords

Atherosclerosis; C reactive protein; Endotoxins; Hemodialysis; Inflammation; Vascular cell adhesion molecule

Indexed keywords

C REACTIVE PROTEIN; ENDOTOXIN; HEMOGLOBIN; SERUM ALBUMIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BODY MASS; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; ENDOTOXEMIA; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; OBSTRUCTIVE UROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CELL ADHESION; ENDOTOXINS; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 84879604555     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12007     Document Type: Article

References (37)

1. Schindler R, Christ-Kohlrausch F, Frei U, Shaldon S. Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens. Clin Nephrol. 2003; 59:447-454.
2. Bommer J, Becker KP, Urbaschek R. Potential transfer of endotoxin across high flux polysulfone membranes. J Am Soc Nephrol. 1996; 7:883-888.
3. Brunet P, Berland Y. Water quality and complications of haemodialysis. Nephrol Dial Transplant. 2000; 15:578-580.
4. Thomé FS, Senger M, Garcez C, Garcez J, Chemello C, Manfro RC. Dialysis water treated by reverse osmosis decreases the levels of C-reactive protein in uremic patients. Braz J Med Biol Res. 2005; 38:789-794.
5. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003; 23:168-175.
6. Stam F, van Guldener C, Becker A, etal. Endothelial dysfunction contributes to renal function associated cardiovascular mortality in a population with mild renal insufficiency: The Hoorn Study. J Am Soc Nephrol. 2006; 17:537-545.
7. Papayianni A, Alexopoulos E, Giamalis P, etal. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in hemodialysis patients: Association with inflammation, dyslipidemia and vascular events. Nephrol Dial Transplant. 2002; 17:435-441.
8. El-Koraie AF, Hazzah WA, Abbas AA, El-Shazly S. Bacteriological monitoring of dialysis fluid in 2 hemodialysis units in Alexandria, Egypt. Saudi Med J. 2007; 28:1234-1238.
9. Vanholder R, van Haecke E, Veys N, Ringoir S. Endotoxin transfer through dialysis membranes: Small- versus large-pore membranes. Nephrol Dial Transplant. 1992; 7:333-339.
10. Pepinsky B, Hession C, Chen LL, etal. Structure/Function studies on vascular cell adhesion molecule-1. J Biol Chem. 1992; 267:17820-17826.
11. Nisbeth U, Hällgren R, Eriksson Ö, Danielson BG. Endotoxemia in chronic renal failure. Nephron. 1987; 45:93-97.
12. Markum HM, Suhardjono, Pohan HT, Suhendro, Lydia A, Inada K. Endotoxin in patients with terminal renal failure undergoing dialysis with re-processing dialyser. Acta Med Indones. 2004; 36:93-96.
13. Taniguchi T, Katsushima S, Lee K, etal. Endotoxemia in patients on hemodialysis. Nephron. 1990; 56:44-49.
14. Nubé MJ, Grooteman MPC. Impact of contaminated dialysate on long-term hemodialysis-related complications: Is it really that important? Nephrol Dial Transplant. 2001; 16:1986-1991.
15. Wiedermann CJ, Kiechl S, Dunzendorfer S, etal. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: Prospective results from the Bruneck study. J Am Coll Cardiol. 1999; 34:1975-1981.
16. Terawaki H, Yokoyama K, Yamada Y, etal. Low-grade endotoxemia contributes to chronic inflammation in hemodialysis patients: Examination with a novel lipopolysaccharide detection method. Therapeutic Apheresis Dial. 2010; 14:477-482.
17. Korevaar JC, Van Manen JG, Dekker FW, De Waart DR, Boeschoten EW, Krediet RT. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004; 15:2916-2922.
18. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant. 2002; 17(Suppl 8):29-32.
19. Helal I, Smaoui W, Hamida FB, etal. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Saudi J Kidney Dis Transpl. 2010; 21:59-62.
20. Panichi V, Migliori M, De Pietro S, etal. The link of biocompatibility to cytokine production. Kidney Int. 2000; 76:S96-103.
21. Arizono K, Nomura K, Motoyama T, etal. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif. 2004; 22:S26-S29.
22. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 2000; 15:1207-1211.
23. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001; 16:1863-1869.
24. Spittle MA. Chronic inflammation and water quality in hemodialysis patients. Nephrol News Issues. 2001; 15:24-26.
25. Ouseph R, Jones S, Dhananjaya N, Ward RA. Use of ultrafiltered dialysate is associated with improvements in haemodialysis-associated morbidity in patients treated with reused dialysers. Nephrol Dial Transplant. 2007; 22:2269-2275.
26. Schouten WEM, Grooteman MPC, van Houte AJ, Schoorl M, van Limbeek J, Nubé MJ. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant. 2000; 15:379-384.
27. Lonnemann G. The quality of dialysate: An integrated approach. Kidney Int. 2000; 58:S112-S119.
28. Bergstroem J, Lindholm B. Malnutrition, cardiac disease, and mortality: An integrated point of view. Am J Kidney Dis. 1998; 32:834-841.
29. Stenvinkel P, Heimbürger O, Lindholm B. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2001; 12:135-140.
30. Stenvinkel P, Barany P, Chung SH, Lindholm B, Heimbürger O. A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. Nephrol Dial Transplant. 2002; 17:1266-1274.
31. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic haemodialysis patients: A prospective study. Kidney Int. 1999; 55:1945-1951.
32. Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrol Dial Transplant. 2002; 17(Suppl 8):33-38.
33. Jager A, van Hinsbergh VWM, Kostense PJ, etal. Increased levels of soluble vascular cell adhesion molecule-1 are associated with risk of cardiovascular mortality in type 2 diabetes: The Hoorn Study. Diabetes. 2000; 49:485-491.
34. Papayianni A, Kalovoulos M, Kirmizis D, etal. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic hemodialysis patients. Nephrol Dial Transplant. 2003; 18:113-119.
35. Bolton CH, Downs LG, Victory JGG, etal. Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001; 16:1189-1197.
36. Peter K, Nawroth P, Conradt C, etal. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol. 1997; 17:505-512.
37. Albertini JP, Valensi P, Lormeau B, etal. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM: Effect of intensive insulin treatment. Diabetes Care. 1998; 21:1008-1013.